Candel therapeutics presents preclinical data at aacr on immunotherapy candidate for induction of tertiary lymphoid structures in solid tumors

Needham, mass., april 09, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the american association for cancer research (aacr) annual meeting, taking place april 5 through 10 in san diego, which focused on a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures (tls), being developed as a novel therapeutic strategy for solid tumors from candel's enlighten™ discovery platform.
CADL Ratings Summary
CADL Quant Ranking